Compass Pathways has become the first company to publish Phase 3 data for a classical psychedelic. Its synthetic psilocybin candidate,...

As mycelium-based innovation moves into mainstream health and nutrition, this research is a reminder that not all mycelium is equal. Chaga is just the case study—but it’s a revealing one.

Article written in partnership with Mabel   a Paris-based company producing functional mushroom and microdosing supplements. Read more on...

For decades, tissue engineering has relied on synthetic polymers, ceramics, and animal-derived collagen to support healing after injury....

With the rise of companies exploring psilocybin based drugs to treat various mental health conditions, the need for greater evidence...